A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02189330 |
Recruitment Status :
Completed
First Posted : July 14, 2014
Last Update Posted : July 15, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Volunteers | Drug: Tafamidis | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | A Phase 1, Open-Label, Randomized, 2-Cohort, Crossover, Single Dose Study to Estimate the Relative Bioavailability of PF 06291826 (Tafamidis) Following Administration of Two Oral Formulations Versus Commercial Capsule in Healthy Subjects Under Fasted Conditions |
Study Start Date : | May 2014 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Tafamidis |
Drug: Tafamidis
20 mg of current commercial formulation. |
Experimental: Tafamudus Free Acid |
Drug: Tafamidis
12.2 mgA free acid tablet. |
Experimental: 20 mg new soft gelatin capsule |
Drug: Tafamidis
20 mg new soft gelatin capsule. |
Experimental: 4 capsules of 20 mg tafamidis of commercial formulation |
Drug: Tafamidis
4 capsules of 20 mg tafamidis of current commercial formulation. |
Experimental: 4 capsules of 12.2 mg tafamidis of free acid tablet |
Drug: Tafamidis
4 capsules of 12.2 mg tafamidis of free acid tablet.. |
- Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] [ Time Frame: 168 hours ]AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).
- Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 168 hours ]
- Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: 168 hours ]Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
- Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 6 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy males or females of non-child bearing potential.
- Body Mass Index (BMI) of 17.5 to 30.5 and total body weight more than 50 kg (110 lbs).
Exclusion Criteria:
- Blood pressure at screening visit of greater than 140 mm Hg (systolic) or 90 mg Hg (diastolic).
- Use of prescription or nonprescription drugs supplements within 7 days prior to 7 days of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189330
Belgium | |
Pfizer Investigational Site | |
Brussels, Belgium, B-1070 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT02189330 |
Other Study ID Numbers: |
B3461030 |
First Posted: | July 14, 2014 Key Record Dates |
Last Update Posted: | July 15, 2014 |
Last Verified: | July 2014 |